Lifebit and Boehringer Ingelheim announce partnership to capture transformational value of health data
PR94684
LONDON, March 1, 2022 /PRNewswire=KYODO JBN/ --
-- Boehringer Ingelheim partners with Lifebit Biotech, Ltd. to build a scalable
data, analytics, and infrastructure platform
-- This collaboration aims at capturing translational disease insights from
large external healthcare biobanks and maximizing value of data for drug
discovery and precision medicine
The leading research-driven biopharmaceutical company Boehringer Ingelheim and
precision medicine software company Lifebit Biotech, Ltd. (Lifebit) today
announce partnership in which Lifebit will support Boehringer Ingelheim in
building a scalable data, analytics, and infrastructure platform within its IT
environment.
Logo - https://mma.prnewswire.com/media/1752753/Boehringer_Ingelheim_Logo.jpg
Logo - https://mma.prnewswire.com/media/1752754/lifebit_logo.jpg
"This platform will play an important part of Boehringer Ingelheim's broader
strategy to capture translational disease insights from large external
healthcare biobanks and ultimately to accelerate the development of innovative
medicines," commented Dr. Jan Nygaard Jensen, SVP and global Head of
Computational Biology and Digital Sciences at Boehringer Ingelheim. Lifebit's
transformational solutions and services will provide standardization of data
sources and types, data curation, identification of data and services that
could be migrated to cloud, and federating data connectivity with third parties.
A key element of this partnership involves Lifebit's CloudOS platform - a
powerful, secure and cutting-edge platform used by a growing number of research
organizations and governments globally, such as Genomics England and The Hong
Kong Genome Project. The federated architecture of this platform securely
brings analytics and computing tools to the data rather than moving sensitive
data around. This promises to unlock the transformational value of biomedical
data by enabling seamless integration with world-leading population genomics
and disease-focused cohorts. Another key benefit of Lifebit's CloudOS will be
the provision of powerful analytic capabilities and global biobank connections
to build a secure "dataland" for analytics and research.
This collaboration follows on the partnership announced in 2021 on utilizing
the Lifebit REAL platform to accelerate detection of the latest disease
outbreaks including transboundary diseases and emerging pathogens, such as
COVID-19.
Lifebit CEO Dr. Maria Chatzou Dunford shared: "We are thrilled to contribute to
Boehringer Ingelheim's vision of harnessing the power of external biobanks and
large-scale clinico-genomic data to transform R&D. We are excited to see how
our technology and global biobank partnerships can transform research
capabilities for Boehringer Ingelheim and deliver powerful impacts for clinical
development pipelines across disease areas."
"We are continuously on the lookout for new opportunities to be able to deliver
faster, better and safer solutions. Therefore, partnering with Lifebit, one of
our partners in this area, is so critical as data and digital technologies can
feed into meaningful scientific exploration, accelerate patient benefits, and
ultimately lead to improved health," added Markus Schümmelfeder, Head of IT at
Boehringer Ingelheim.
About Lifebit Biotech, Ltd.
Lifebit builds enterprise data platforms for use by organisations with complex
and sensitive biomedical datasets. Lifebit's patented federated technology
securely unlocks access to biomedical data. From providing Trusted Research
Environments for national precision medicine programmes to enabling
pharmaceutical companies to discover new drug targets faster, Lifebit empowers
customers to transform how they leverage sensitive biomedical data.
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that improve the
lives of humans and animals. As a leading research-driven biopharmaceutical
company, the company creates value through innovation in areas of high unmet
medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim
takes a long-term perspective. Around 52,000 employees serve more than 130
markets in the three business areas, Human Pharma, Animal Health, and
Biopharmaceutical Contract Manufacturing.
More information about Boehringer Ingelheim can be found at
www.boehringer-ingelheim.com
Boehringer Ingelheim's Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim,
Germany and is intended to provide information about our global business.
Please be aware that information relating to the approval status and labels of
approved products may vary from country to country, and a country-specific
press release on this topic may have been issued in the countries where we do
business.
SOURCE: Lifebit Biotech, Ltd.
CONTACT: Bettina Dold, +1-412-983-0048, bettina@lifebit.ai
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。